AKR1C3 is overexpressed in 90% of hepatocellular tumors and in 50% of pancreatic tumors, and there is a significant unmet need for better treatments in these cancers, especially for patients whose disease has progressed after surgery and/or systemic chemotherapy. Here, AKR1C3 is linked to cancer.